MedTrace Logo

Catatonia in Nodding Syndrome and Lorazepam Treatment

NCT02462109 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2015-06-03

No results posted yet for this study

Summary

Nodding Syndrome is an enigmatic neuropsychiatric syndrome affecting children and adolescents mostly in Eastern Africa. The symptoms of Nodding Syndrome and catatonia seem to overlap. The researchers' objectives in this study were to investigate the presence and types of catatonic symptoms in children with Nodding Syndrome and observe their response to one or two doses of lorazepam, the first-line treatment for catatonia.

Conditions

  • Catatonia
  • Nodding Syndrome

Interventions

DRUG

Lorazepam

Lorazepam was given based on the weight of the child with Catatonia. The lower dose (0.5 mg) was used as starting dose for patients with \<30 kg body weight, while the higher dose (1 mg) as the starting dose for patients with \>30 kg body weight.

Sponsors & Collaborators

  • University of Mississippi Medical Center

    collaborator OTHER

  • Makerere University

    lead OTHER

Principal Investigators

  • Angelina Kakooza-Mwesige, MMed · Makerere University College of Health Sciences, Kampala, Uganda

  • Dirk M Dhossche, MD, PhD · University of Mississippi Medical Center, Jackson, USA

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
10 Years
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2013-03-31
Completion
2013-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02462109 on ClinicalTrials.gov